BioSpace News Archive

Additional data on first non-invasive medical device cleared by the FDA for OCDdemonstratedthat 73% responded positivelyto Deep TMS,and durability of therapeutic effect was shown

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison , M.D., Chief Executive Officer of Syndax, will present at the Stifel 2020 Virtual Healthcare Conference on Wedne

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020.

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell , will participate in four upcoming virtual conferences in November and December of 2020. Presentations Details: 2020 Stifel Virtual Health

CVS Health Corporation announced that Daniel Finke has been named Executive Vice President, CVS Health and President, Health Care Benefits Segment effective February 1, 2021.

On Wednesday, November 18, 2020, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will present at the Stifel 2020 Virtual Healthcare Conference at 3:20 p.m. Eastern Time. You may access the live audio webcast, as well as a replay on the company’s investor relations website, https://investors.csi360.com/events-and-presentations/events-calendar/default.aspx . A

-Underwritten Public Offering and Nasdaq Listing Completed in September 2020 -Positive Phase 3 Interim Analysis Reported with an Estimated 37 percent More Recoveries Observed in the Lenzilumab Arm Versus Current Standard of Care

Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments using its CRISPR/Cas9 genome editing technology. This pilot development program is part of the Gates Foundation’s broade

The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the Stifel Virtual Healthcare Conference